<DOC>
	<DOC>NCT00938860</DOC>
	<brief_summary>This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.</brief_summary>
	<brief_title>Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Inclusion criteria: Liver transplantation performed at least 6 months and up to 5 years prior randomization and due to HCV cirrhosis, with or without pretransplant hepatocellular carcinoma (HCC) within Milan or UCSF criteria Immunosuppresive regimen based on tacrolimus b.i.d. (twice or once daily) for at least 6 months prior randomization Diagnosis of HCV genotypes 1 or 4 infection prior to transplantationconfirmed at screening Indication of treatment with PegIFN and ribavirin due to histological evidence of chronic HCV infection defined as a fibrosis stage equal or greater than 1 using the IshakKnodell scoring system (IK ≥1) in a liver biopsy performed at screening or up to 4 months prior to randomization. Exclusion criteria: Serum creatinine &gt;150 μmol/L (1.6 7 mg/dL) or eGFR &lt; 50 ml/min (4variable Modification of Diet in Renal Disease [MDRD CockcroftGault formula]) Multiorgan transplant recipients Recent episode of steroidtreated acute rejection (AR) within 3 months prior to randomization, or &gt;1 episode of steroidtreated AR in the last 6 months, or any number of steroidresistant AR episodes in the last 6 months including evidence of chronic rejection or ductopenia Evidence of conditions that could cause graft dysfunction other than HCV infection Patients with signs of decompensated liver disease, defined as presence of ascites, variceal bleeding, encephalopathy or deteriorated hepatic synthetic function (albumin &lt;3.5g/dL or, total direct bilirubin &gt;1.5mg/dL or, INR &gt;1.5) Coinfection with HIV or Hepatitis B (defined as HBsAgpositive) at screening Use of mTOR inhibitors (everolimus or sirolimus) in the 6 months prior to screening Antiviral treatment for HCV administered at any time after liver transplantation Patients on daily doses of corticosteroids higher than 5 mg/day Patients with fibrosing cholestatic hepatitis Patients with current diagnosis of malignancies, including lymphoproliferative disorders Patients with platelet count &lt;70,000/mm3 or neutrophiles &lt;1,500/mm3 History of HCC outside Milan criteria based on radiology or UCSF criteria based on analysis of the explant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>anti-viral therapy</keyword>
</DOC>